tetano
Editor, Senior Moderator
Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
A human monoclonal antibody blocking SARS-CoV-2 infection.
Wang C[SUP]1[/SUP], Li W[SUP]1[/SUP], Drabek D[SUP]2,[/SUP][SUP]3[/SUP], Okba NMA[SUP]4[/SUP], van Haperen R[SUP]2,[/SUP][SUP]3[/SUP], Osterhaus ADME[SUP]5[/SUP], van Kuppeveld FJM[SUP]1[/SUP], Haagmans BL[SUP]4[/SUP], Grosveld F[SUP]2,[/SUP][SUP]3[/SUP], Bosch BJ[SUP]6[/SUP].
Author information
Abstract
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.
PMID:32366817DOI:10.1038/s41467-020-16256-y
A human monoclonal antibody blocking SARS-CoV-2 infection.
Wang C[SUP]1[/SUP], Li W[SUP]1[/SUP], Drabek D[SUP]2,[/SUP][SUP]3[/SUP], Okba NMA[SUP]4[/SUP], van Haperen R[SUP]2,[/SUP][SUP]3[/SUP], Osterhaus ADME[SUP]5[/SUP], van Kuppeveld FJM[SUP]1[/SUP], Haagmans BL[SUP]4[/SUP], Grosveld F[SUP]2,[/SUP][SUP]3[/SUP], Bosch BJ[SUP]6[/SUP].
Author information
Abstract
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.
PMID:32366817DOI:10.1038/s41467-020-16256-y